Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLLGlobeNewsWire · 4 days ago
Ascentage Pharma Stock Could More Than Double: AnalystBenzinga · Oct 16, 2026
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 4% – Should You Buy?Defense World · Oct 12, 2026
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts AheadMarketBeat · Oct 10, 2026
3 Small-Cap Stocks With Catalysts That Could Put Them in the SpotlightMarketBeat · Oct 5, 2026
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Average Recommendation of “Buy” from BrokeragesDefense World · Sep 21, 2026Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 18, 2026 | -$0.22 | -$1.30 | Miss |
| Mar 24, 2026 | -$0.83 | -$0.65 | Beat |
| Aug 20, 2025 | – | -$0.96 | |
| Mar 27, 2025 | $0.02 | -$1.00 | Miss |
| Aug 22, 2024 | – | $0.31 | |
| Dec 31, 2023 | – | -$1.02 |